Hepatitis B virus causes acute and chronic inflammation of liver which may leads to hepatocellular carcinoma, cirrhosis and death. Chronic hepatitis B is usually accompanied by the presence of detectable hepatitis B surface antigen (HBsAg) in the blood for greater than 6 months. The presence of hepatitis B envelope antigen (HBeAg) is related to higher rates of viral replication leading to more infection. Objective: Currently vaccination for prevention of hepatitis B is present and its treatment includes pegylated interferon α, lamivudine, telbivudine and entecavir (nucleoside analogues) and adefovir (nucleotide analogues). This treatment is partially effective and has significant dose dependent side effects and resistance after long term use. Hence, there is a need to develop new more safe and potent agents against hepatitis B from medicinal plants. This review illustrates the description of medicinal plants, family, their active ingredients, parts and extracts used to treat hepatitis B by their mechanisms. The pharmaceutical companies are striving to discover appropriate alternative and natural inhibitors of targeting different steps of HBV life cycle, because single plant contains an invaluable number of active ingredients which could help in the manufacture of pharmaceutical grade proteins and has wide spectrum of antiviral activity. However, information of antiviral activity of plants is still inadequate.
Introduction
Hepatitis B, a devastating ailment is distressing over 2 billion population all over the world. Amongst those more than 360 million people suffering from chronic hepatitis B (Lavanchy, 2004) . Every year, the death rate is 0.5-1.2 million people owing to chronic hepatitis, cirrhosis as well as liver cancer according to WHO. In Pakistan, over 15 million peoples have been infected with hepatitis B because of ignorance of vaccination with carrier rate of 3-5% (Ott, 2012) . HBV is transmitted via blood transfusion, use of unhygienic tools for shaving, unsterilized instruments during surgery as well as use of contaminated syringes. Hepatitis is spread via sexual means owing to several sexual partners as well as via diseased mother to children (Enemuor et al., 2012) . Patients undergoing dialysis for more than two years are at greater risk for hepatitis (Wasley et al., 2008 Table  1 .
Pathogenesis of Hepatitis B virus (HBV)
HBV, a moderately double stranded (ds) DNA virus has family of hepadnaviridae. This virus contains nucleocapsid having DNA genome of 3.2 kb and DNA polymerase. Assembled hepatitis B core antigen form nucleocapsid which is protected by lipid envelope comprising of hepatitis B envelope antigen (HBeAg) as well as hepatitis B surface antigen (HBsAg) (Baumert et al., 2014) . HBV replication begins when virus enters host cell and releases its DNA into nucleus. First step is attachment of virus having pre S1 receptors at its surface and heparin sulfate proteoglycans on liver cells. Then virus penetrates hepatocytes via endocytosis or fusion which depends on host factors involving the endosome synthesis. Nucleocapsid of virus, having partially double stranded relaxed circular (rcDNA), is secreted into cytoplasm prior to reaching to nucleus of hepatocytes. Capsid brings its rcDNA to nucleus by nuclear pore complex (NPC) (Ezzikouri et al., 2014) which is due to association between nuclear localization signaling (NLS) in C-terminal of capsid protein and nuclear import receptors (importin-α and β). After that rcDNA is converted into covalently closed circle DNA (cccDNA) via viral DNA polymerase. cccDNA is used as template for synthesizing of pregenomic RNA which at that time undergo assembly of viral DNA as well as mRNA results in encoding entirely new viral proteins. During the reverse transcription of pregenomic RNA into complementary DNA, the pregenomic RNA is tainted. Initially HBV surface proteins are formed along with polymerized in rough endoplasmic reticulum. The proteins are transferred into ER and pre golgi sections and growing of nucleocapsid is started. Consequently, whole virus is liberated from host cell for stating new life cycle (Lu and Block, 2004 ).
Hepatitis B virus and medicinal plants
Boehmeria nivea (BN) is traditionally used for curing hepatitis B. For screening of activity of ethanolic extract of leaves of BN against hepatitis B virus in vivo, viremia HBV mice models which were generated by subcutaneous inoculation of hepatoma G tumor cell lines (HepG2 2.2.15) for period of 13 days, were used. A result exhibited that BN extract given orally and intraperitoneally effectively inhibited the formation of HBV DNA and HBsAg. However intraperitoneal administration suppressed serum HBV DNA levels more than oral (Chang et al., 2010) . In earlier investigations, ethanolic extract of the roots of BN could diminish the supernatant hepatitis B virus (HBV) DNA in HBV producing HepG2 2. Methanolic extracts of leaves of Enicostemma axillare and seeds of Terminalia bellerica, blocked HBV DNA polymerase while methanolic extract of leaves of Hybanthus enneaspermus blocked HBs Ag binding in plasma of patients in vitro using ELISA kits (Anbalagan et al., 2015) . Alcoholic extract of leaves of Acanthus ilicifolius decreased transaminase levels such as ALT and AST in duck hepatitis B virus serum but did not significantly suppress hepatitis B virus DNA in ducks. Thus, extract had hepatoprotective effect against HBV induced liver damage (Wei et al., 2015) . Gymnema sylvestre demonstrated antiviral activity and its active ingredients inhibited HBsAg binding and HBV DNA polymerase (Subashini and Rajendran, 2015) . Methanolic extract of Mimosa pudica inhibited HBs Ag binding to its receptor at 5mg/ml (invitro) which indicated that it had capability to act as novel entry inhibitor during HBV infection by using hepatitis B positive blood (Rohan et al., 2014) . 
CONCLUSION
Although there are many drugs available for treatment of hepatitis B and vaccination is also effective against virus but due to side effects and resistance associated with these drugs, there is need to explore safer and most potent drugs. Natural products are considered good candidates with strong antihepatitis B activity. This review illustrates the description of medicinal plants used to treat hepatitis B. Forthcoming energies should be dedicated to enhance and progress these principal complexes into effective anti HBV agents for experimental claims. There is limited data available illustrating mechanism of action of medicinal plants with antihepatitis B activity. Thus, mechanisms of function and safety of herbs remain incomprehensive and even controversial. The toxicological data for screening the safety of medicinal plants is not discussed and people have blind faith in herbal treatment. For determination of activity of medicinal plants against hepatitis B, various HBV animal models for instance HBV transgenic mice and duck model have been used thus, are very expensive but these representations can only describe a portion of the mechanism of anti-hepatitis B medicines. In several findings, cell lines such as HepG 2 2.2.15 within mice were recognized to mimic the occurrence of HBV viremia, for the reason that viruses produced from HepG 2 2.2.15 cells have been defined to be transmittable.
